Harmony Biosciences Holdings (HRMY) Income towards Parent Company (2019 - 2026)

Harmony Biosciences Holdings (HRMY) reported Income towards Parent Company of $32.5 million for Q1 2026, down 28.69% on a YoY basis from $45.6 million in Q1 2025, and down 50.22% sequentially from $65.3 million in Q4 2025.

Harmony Biosciences Holdings (HRMY) Income towards Parent Company (2019 - 2026) Analysis & Trends

Harmony Biosciences Holdings (HRMY) has 8 years of Income towards Parent Company data on file, last reported at $32.5 million in Q1 2026.

  • For the quarter ending Q1 2026, Income towards Parent Company fell 28.69% year-over-year to $32.5 million; the trailing twelve-month figure through Mar 2026 stood at $188.4 million (up 23.36% YoY), and the FY2025 full-year result was $201.5 million, up 38.47% from the prior year.
  • Income towards Parent Company fell to $32.5 million in Q1 2026, from $65.3 million in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of $87.9 million in Q3 2022 to a low of $11.6 million in Q2 2024.
  • A 5-year average of $40.6 million and a median of $38.5 million in 2023 frame the typical range for Income towards Parent Company.
  • Across the five-year window, Income towards Parent Company surged 1014.17% in 2022 and sank 66.21% in 2024, its largest moves.
  • Tracing HRMY's Income towards Parent Company over 5 years: stood at $48.5 million in 2022, then slumped by 45.15% to $26.6 million in 2023, then surged by 85.95% to $49.5 million in 2024, then soared by 31.91% to $65.3 million in 2025, then plunged by 50.22% to $32.5 million in 2026.
  • Business Quant data shows HRMY's Income towards Parent Company at $32.5 million in Q1 2026, $65.3 million in Q4 2025, and $50.9 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Harmony Biosciences Holdings 2.09 Bn 1.57 Bn 170.88 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 32.49 Mn
Dec 31, 2025 65.26 Mn
Sep 30, 2025 50.87 Mn
Jun 30, 2025 39.78 Mn
Mar 31, 2025 45.56 Mn
Dec 31, 2024 49.48 Mn
Sep 30, 2024 46.09 Mn
Jun 30, 2024 11.59 Mn
Mar 31, 2024 38.33 Mn
Dec 31, 2023 26.61 Mn
Sep 30, 2023 38.46 Mn
Jun 30, 2023 34.30 Mn
Mar 31, 2023 29.49 Mn
Dec 31, 2022 48.51 Mn
Sep 30, 2022 87.94 Mn
Jun 30, 2022 23.53 Mn
Mar 31, 2022 21.49 Mn
Dec 31, 2021 22.71 Mn
Sep 30, 2021 -9.62 Mn
Jun 30, 2021 14.12 Mn